News
LUNG
9.38
+21.50%
1.66
Pulmonx Is Maintained at Buy by Canaccord Genuity
Dow Jones · 4h ago
Pulmonx Price Target Cut to $15.00/Share From $16.00 by Canaccord Genuity
Dow Jones · 4h ago
Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15
Benzinga · 5h ago
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Dow Jones index gained over 50 points on Thursday. Shares of C.H. Robinson Worldwide, Inc. Rose sharply after the company reported better-than-expected first-quarter financial results. The company's quarterly sales came in at $4.412 billion. Aspen Aerogels shares jumped 37.5% to $20.92.
Benzinga · 9h ago
Pulmonx Surge After Strong 1Q Performance
Pulmonx posts narrower first-quarter loss than analysts had been expecting. The developer of minimally invasive treatments for lung disease posted a loss of $13.7 million. The stock was up 25% at $9.63 after the opening bell. Revenue jumped 30% to $18.9 million.
Dow Jones · 10h ago
PULMONX SHARES RISE 28.3% AFTER Q1 REVENUE BEAT
Reuters · 10h ago
Market-Moving News May 2nd
Allarity Therapeutics shares are trading higher. Stenoparib shows a clear clinical benefit in advanced ovarian cancer. Pulmonx shares trading higher after the company reported better-than-expected Q1 financial results. Emergent Biosolutions shares are also trading up.
Benzinga · 11h ago
Pulmonx (LUNG) Receives a Buy from Stifel Nicolaus
TipRanks · 11h ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Several companies release results for the first quarter of 2024 today. Emergent BioSolutions stock is rocketing close to 70% alongside strong Q1 earnings. Carvana shares are soaring more than 37% alongside its Q1 2024 earnings. Fastly stock is plummeting over 33% on a weak earnings forecast.
Investorplace · 12h ago
Analyst Recommendation Report Summary: Insights and Strategic Investment Perspectives
TipRanks · 13h ago
PULMONX CORP <LUNG.O>: CANACCORD GENUITY CUTS TARGET PRICE TO $15 FROM $16
Reuters · 16h ago
U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Mastercard, Metagenomi, Ziff Davis and 3M among companies. Analyst cuts target price to $510 from $520 for Mastercard. 3M raises price objective to $105 from $100.
Reuters · 17h ago
Pulmonx Corp reports results for the quarter ended in March - Earnings Summary
Pulmonx Corp reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 36 cents per share. Revenue rose 29.7% to $18.85 million from a year ago. Pulmonx shares have fallen by 16.7%.
Reuters · 18h ago
PULMONX CORP <LUNG.O>: PIPER SANDLER CUTS TARGET PRICE TO $14 FROM $17
Reuters · 20h ago
LUNG Stock Earnings: Pulmonx Beats EPS, Beats Revenue for Q1 2024
Pulmonx just reported results for the first quarter of 2024. Pulmonx reported earnings per share of -36 cents. This was above the analyst estimate for -46 cents. The company reported revenue of $18.85 million, 5.39% better than expected.
Investorplace · 23h ago
VRM, FRSH and MRAM are among after hour movers
On the Move VRM, FRSH and MRAM are among after hour movers. Pulmonx Corporation, Vroom and CRISPR Therapeutics gain. Remitly Global, DoorDash and Etsy are among the losers in this week's list.
Seeking Alpha · 1d ago
PULMONX CORP SAYS CONTINUES TO EXPECT GROSS MARGIN FOR FULL YEAR 2024 TO FALL WITHIN RANGE OF 74% TO 75%
Reuters · 1d ago
Pulmonx Corp <LUNG.OQ> expected to post a loss of 46 cents a share - Earnings Preview
Pulmonx Corp expected to post a loss of 46 cents a share. The company is expected to report a 23.1% increase in quarterly revenue to $17.893 million. Analysts expect Pulmonx to report results on May 1 for the period ending March 31 2024.
Reuters · 3d ago
Weekly Report: what happened at LUNG last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at LUNG last week (0415-0419)?
Weekly Report · 04/22 09:09
More
Webull provides a variety of real-time LUNG stock news. You can receive the latest news about Pulmonx Corp through multiple platforms. This information may help you make smarter investment decisions.
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.